Drug Profile

GRI 0729

Alternative Names: GRI-0729

Latest Information Update: 04 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GRI Bio
Class Anti-inflammatories
Mechanism of Action Natural killer T cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Unspecified

Highest Development Phases

Preclinical Unspecified

Most Recent Events

27 Jun 2024 GRI Bio has patent protection for “Prevention and Treatment of Inflammatory Conditions” in South Korea
12 Oct 2023 GRI 0729 is available for licensing as of 11 Oct 2023. https://gribio.com/our-pipeline/
31 Jan 2023 GRI Bio has patent protection for GRI 0729 in the USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com